Phio Pharmaceuticals Corp (PHIO) - Utang jangka cendhak perusahaan

Phio Pharmaceuticals management is strictly adhering to the clinical trial plan, maintaining shareholder confidence. However, the global technological gap and sanctions are complicating the supply of reagents for RNA therapy. The short-term debt balance shows that the indicator stands at 0.00, which is critical for assessing the viability of the business as it develops the INTASYL platform for B2B licensing in the immuno-oncology sector.

This indicator aggregates all of the issuer's current liabilities to creditors, enabling an assessment of liquidity and the degree of financial risk associated with working capital management. By analyzing fluctuations in short-term debt, investors gain insight into the actual credit policy of Phio Pharmaceuticals (PHIO), which is critical for sustaining its highly specialized RNA interference platform given the dependence on the success of a limited development portfolio.